38,034 Shares in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC purchased a new position in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 38,034 shares of the biopharmaceutical company’s stock, valued at approximately $760,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Captrust Financial Advisors raised its stake in shares of Intercept Pharmaceuticals by 564.2% during the first quarter. Captrust Financial Advisors now owns 1,096 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 931 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 1,072.5% during the second quarter. Nisa Investment Advisors LLC now owns 4,045 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 3,700 shares during the last quarter. Credit Agricole S A raised its stake in shares of Intercept Pharmaceuticals by 142.4% during the first quarter. Credit Agricole S A now owns 4,000 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 2,350 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $152,000. Finally, Panagora Asset Management Inc. increased its stake in Intercept Pharmaceuticals by 2,542.4% in the second quarter. Panagora Asset Management Inc. now owns 8,482 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 8,161 shares in the last quarter. 66.69% of the stock is owned by institutional investors and hedge funds.

ICPT has been the subject of several recent analyst reports. Wedbush lowered their target price on shares of Intercept Pharmaceuticals from $74.00 to $67.00 and set an “outperform” rating for the company in a research note on Monday, August 2nd. SVB Leerink reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, May 31st. The Goldman Sachs Group downgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating and lowered their target price for the company from $17.00 to $10.00 in a research note on Friday, August 20th. Robert W. Baird reaffirmed a “buy” rating and issued a $52.00 target price on shares of Intercept Pharmaceuticals in a research note on Sunday, August 1st. Finally, Royal Bank of Canada upped their target price on shares of Intercept Pharmaceuticals from $22.00 to $23.00 and gave the company a “sector perform” rating in a research note on Friday, July 30th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.84.

ICPT traded up $0.28 during trading hours on Wednesday, hitting $15.38. 7,495 shares of the company’s stock were exchanged, compared to its average volume of 1,026,544. Intercept Pharmaceuticals, Inc. has a 1-year low of $11.60 and a 1-year high of $43.16. The stock’s 50-day moving average is $15.53 and its two-hundred day moving average is $18.60. The stock has a market cap of $510.63 million, a price-to-earnings ratio of -2.94 and a beta of 1.47.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, July 29th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.91. The business had revenue of $96.58 million for the quarter, compared to analyst estimates of $82.64 million. As a group, sell-side analysts anticipate that Intercept Pharmaceuticals, Inc. will post -3.87 EPS for the current fiscal year.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.

See Also: Why is cost of goods sold important?

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.